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ABSTRACT
Malaria remains one of the most important infectious diseases worldwide considering that
40% of the world’s population live in health risk areas and millions of febrile episodes due
to malaria infection occur annually in children under the age of five in Africa alone and
almost 3 million patients, primarily children, die each  year. Among the various measures
envisaged, to contain the disease, the concept of a vaccine to protect humans against
malaria appears particularly attractive. The development of an effective malaria vaccine
represents one of the most important approaches to  provide cost-effective intervention,
in addition to currently available malaria control strategies. Here, we review malaria as a
public health problem and the status and promise in malaria vaccine development.
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INTRODUCTION
Malaria is one of the most important infectious diseases in the world and the scourge of
many developing countries. There are an estimated 300-500 million cases of malaria each
year, resulting in over 1 million deaths, mainly of children under five years in sub-Saharan
Africa..[1]  Furthermore, tens of millions of non-immunes have been highlighted by the
impact of malaria on military operations and wars, and catastrophic natural disasters such
as famines and floods. During the twentieth century, the United States military forces lost
more person days to malaria than to bullets in every operation conducted in a malarious-
region. It is only natural therefore that  major efforts are underway to develop an efficacious
malaria vaccine.
The parasite has a complex life cycle. Sporozoites are inoculated by the Anopheles
species mosquitoes that feed on humans from dusk until dawn. The extracellular sporozoites
are present in the bloodstream for <1 hour. They invade hepatocytes where a single,
uninucleate sporozoite develops during 2 to 10 days, depending on the plasmodium spp.  (5
to 6 days for P. falciparum), to a mature liver stage schizont. The liver stage parasite
ruptures releasing up to 30,000 uninucleate merozoites, each of which can invade an
erythrocyte, and subsequently develop during 2–3 days (43 to 48 hours for P. falciparum)
to a mature erythrocytic stage schizont with 10–30 merozoites. When the infected erythrocyte
ruptures, it liberates parasite-derived toxins and merozoites, and the released merozoites
invade other erythrocytes.  In some instances the merozoite will develop within the
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erythrocyte to the sexual stage called gametocytes. When a mosquito ingests erythrocytes
containing gametocytes, the parasites develop in the midgut of the mosquito to gametes
that are released from the erythrocytes. This is followed by fertilisation of the female by the
male gamete leading to zygote formation, and subsequently ookinete, oocyst, and sporozoite
development. Only the asexual cycle is associated with pathology.
MALARIA AS A PUBLIC HEALTH PROBLEM
Malaria has been estimated to represent 2.3 % of the overall global disease burden and 9 %
in Africa, [2] ranking third among the infectious disease threats, after pneumococcal acute
respiratory infections (3.5%) and tuberculosis (2.8%). In 1990, malaria was responsible for
the loss of 31,705 000 disability-adjusted life-years (DALYs). The disease is often linked to
the movement of refugees or population seeking work and to environmental change, including
forestry, mining and water development projects.[3] By the year 2000, the current WHO
Global Malaria Control Strategy aims to reduce malaria mortality by at least 20% in at least
75% of the affected countries. This strategy recognises that multiple varied transmission
and operational drug-resistant patterns worldwide lead to different epidemiological patterns/
paradigms of malaria illness for which certain risks are particularly important and certain
approaches to control are more likely to succeed than others.[4] Because malaria represents
a moving target, control programmes need to identify and monitor epidemiological patterns.[5]
However, pregnant women and children under five years continue to constitute two of the
most important risk groups. To control malaria, better ways must be found to apply existing
control methods, improved tools must be developed and solutions need to be identified to
circumvent and combat emerging problems including social/political unrest, the widespread
resistance of malaria parasite to existing drugs [6] and the potential change in the distribution
and incidence of malaria due to anthropogenic climate change.[7]
The cost of physical intervention methods intended to interfere with the transmission
of the disease such as bednets and window screens is often prohibitive and such measures
are not highly effective. This is compounded by and the availability and cost of prophylactic
drugs which precludes their use by many of the individuals who need them the most.
Moreover, the emergence of drug-resistant parasites means that many of the prophylactic
drugs that were effective in the past are no longer useful, and many of the newer generation
drugs are associated with rare but significant side-effects, such as fatal heart rhythms
(halofantrine), fatal skin disease (pyrimethamine/sulfadoxine), neurological disturbances
(mefloquine), or gastrointestinal distress (doxycycline). The increase in insecticide-resistant
vectors that transmit malaria, and the undesirable environmental impact of those insecticides
shown to be most effective means chemical interventions are frequently not useful in
combating the disease. These factors emphasise the urgent need for the development of an
effective malaria vaccine.
MALAYSIAN SCENARIO
Incidence of Malaria continues to decrease from almost 60,000 cases in 1995 to only 6154 in
2004 (Table 1).  In 2004, Sabah,  followed  by Sarawak, had the majority  of cases in Malaysia,
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 Table 1. Immune mechanisms related to vaccines directed against malaria parasite stages
in the life cycle.
Stage/target Immune response/ Rational for approach
effector mechanism
Pre-erythrocytic stages
1. Sporozoite Antibodies Sporozoite secretion limited to minutes.
2. Hepatic forms CD4+ and CD8+ T cells, Parasite develops inside hepatic cells,
including CTL activity which can express antigens and MHC
and cytokine secretion molecules recognised by T cells.
Antibodies Cell surface expression of parasite
antigens.
Asexual blood stage
Merozoite/infected Antibody-includes the inhibition No MHC molecules expressed on
erythrocytes of red blood cell invasion, infected erythrocytes. Anti-disease
ADCC activity; inhibition of vaccine can be directed to cytokine-
cytoadherence, anti-toxin inducing processed parasite antigens or
activity, anti-cytokines or toxins.
reduction of free radicals.
Sexual stage
Gametocyte/gamete/ Antibody – includes blocking Sporogonic development is a crucial
aokinete activity pre-and/or post- target; no host MHC molecules involved
fertilisation in the mosquito. in this stage of  parasite development.
Cell-mediated immunity- No MHC molecules expressed on
cytokines? infected cells.
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; CTL, cytolytic T lymphocytes;
MHC, major host-compatibility complex.
with less than a quarter in Penisular Malaysia, with Pahang and Johor topping the list
(Ministry of  Health 2004) (Table 2).   With regard to malarial parasite distribution, Plasmodium
vivax (51.46 %)  still predominates  followed by P.  falciparum at 40.56% whilst only 5.35%
are P. malaria. (P. ovale has not been detected in Malaysia).[8]
CLINICAL IMPLICATIONS
Children face the greatest risk of malaria complications with the highest mortality in those
below 5 years [10] whilst in pregnant women, the risk  of prematurity, abortion or stillbirth
exists.[11]  The classic symptoms of malaria are high fever with chills and rigours, sweating
and rigours; depending on the infection species, fever appears every or every third day.
Anaemia and thrombocytopenia are common with pallor and jaundice that may occur due to
hemolysis.
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Figure 1. Incidence and incidence rate of malaria in Malaysia, 1995 - 2004
Figure 2. Malaria cases and incidence rate by geographical area (state), 2004
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Infection with P. falciparum is potentially fatal, with the severe form manifesting with
any of the following viz, cerebral malaria, hypoglycaemia (quinine associated), non-
cardiogenic pulmonary edema, renal failure and even vascular collapse.[9]  Therefore the
emergence of  P falciparum resistance compounds the treatment issue even further. It has
been reported that in Penisular Malaysia, 28.5 % of falciparum malaria was  resistant to
chloroquine but by mid-1990s, it had risen to about 60 %, according to Hakim et al.  [12]  Even
more worrying is that a combination of Fansidar (sulpadoxine  & pyrimethamine) and
chloroquine  encounterd 50-60 %  resistance  according  to 2001 records in Malaysia.
In view of the difficulty of treating falciparum malaria, a strategy to combat rapid
resistance has to be formulated, with combination therapy using drugs with differing anti
malarial mechanisms.  The most widely advocated combination is ACT’s Artemesinin based
combination therapies. Artemesinin reduces gametetocyte carriage and is thus a good
transmission blocking agent;  at the same time it is efficacous, rapid acting and well tolerated.
[13] Existing combinations include Artemether-lumefantrine and Artesunate-mefloquine.
Another strategy to circumvent the problem of resistance arising from existing drugs is to
search for suitable vaccines, an imperative that has become even more critical.
VACCINATION PROSPECTS
The primary goal of malaria vaccine research is to develop and field a vaccine that prevents
the majority of naïve recipients from developing any clinical manifestations of disease after
exposure, and to prevent the development of severe disease and death in those individuals
who  become ill by limiting the effects of blood stage infection.[8]  The first step should be
to develop  a vaccine designed to prevent any clinical manifestations of malaria completely
and the populations that would benefit from such a vaccine would be travelers, deployed
military personnel, and non-immune individuals living in non-malarious areas of countries
with malaria. The second is for a vaccine designed to prevent mortality and severe morbidity,
by limiting the effects of blood stage infection by reducing parasite replication, reducing
cytoadherence, and/or inhibiting the effects of toxic materials released by the parasite.[14]
The populations that would benefit from this are individuals, primarily children, residing in
malarious areas.
The development of a vaccine against malaria presents formidable obstacles in terms
of parasite biology and host immune responses. During its complicated life cycle, the
parasite exists extracellularly in the blood stream of the host, within cells that express major
histocompatibility complex (MHC) molecules (erythrocytes), and within the mosquito vector.
The antigens that are the targets of protective immune responses are expressed at different
stages of the parasite’s life cycle, and different arms of the immune system are required to
attack the parasite at these different stages.[15] Moreover allelic and antigenic variation of
the parasites and variant disease expression based on transmission dynamics and genetic
background of the host are well established. These factors suggest that only a similarly
complex vaccine may provide sustainable protection against malaria.
The development of an effective malaria vaccine represents one of the most important
strategies for providing an efficacious cost-effective addition to the currently available
malaria control interventions. Recently the relative cost-effectiveness of a hypothetical
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vaccine against Plasmodium falciparum compared to currently available interventions for
use in high risk groups in Africa has been estimated. A malaria vaccine that could be
implemented through the existing Expanded Programme on Immunisation (EPI), with costs,
schedule etc, that would reduce the overall childhood mortality by 30% or more, with a
duration of a  three-year immunity  or more, would represent a very cost effective intervention
strategy.  Approximately USD 1 – 20 per healthy  year of life could be saved.  However, as no
single intervention tool is likely to represent a panacea for malaria, an effective vaccine
would be applied together with other appropriate cost-effective methods.
Over the past decade, there has been considerable progress in the identification of
vaccine candidate antigens and their genes but, owing to the complexity and cost of vaccine
development and the relative lack of commercial interest, only recently have they entered
clinical trials. Moreover, appropriate in vitro functional assays for predicting protection
have been difficult to identify and validate and they exist only for evaluating the potential
of transmission blocking vaccines to inhibit parasite development in the mosquito. Indeed
even the membrane-feeding assay for measuring functional transmission blocking activity
remains to be validated in the field.  Immune mechanisms thought to be involved in conferring
protection to the different stages of malaria parasite are given in Table 1. It should be noted
that vaccines directed at the asexual blood stage antigens may constitute anti-disease
vaccine and that the objective of such vaccine is to reduce severe morbidity and mortality
resulting from  malaria, and not necessarily to provide protection against infection (i.e,
sterile immunity) in the vaccinated individual. Indeed it is extraordinarily rare for sterile
immunity to malaria to be ever developed in nature.
Immunisation of experimental animals with irradiated sporozoites induced complete
protection against subsequent challenge with the plasmodial parasite in question. Based
on these observations, human volunteers were subjected to multiple mosquito bites with P.
falciparum or P. vivax infected, irradiated mosquitoes. The vaccinated individuals became
resistant to sporozoite challenge, thus proving the principle that experimental immunisation
of humans against malaria is feasible. Unfortunately, to date, the technology involved in
executing the immunisation process using irradiated sporozoites does not lend itself to a
practical, cost effective vaccination strategy. Although in vitro culture systems have been
developed for the continuous culture of  P. falciparum parasites and provision of asexual
blood stage parasites and gametocytes, production of sufficient quantities for vaccination
purposes is not feasible. Genetic manipulation may create new opportunities by transforming
parasites to allow for continuous culture in the absence of red blood cells. In subsequent
studies, several purified native and recombinant antigens, e.g. Merozoite Surface Protein-1
(MSP-1), Apical Membrane Protein-1 (AMA-1) or Serine-rich Protein (SERA) have been
found to induce strain-specific immunity in experimental animals.
Trials of malaria vaccines have been carried out in an empirical way, with the focus in
the 1980s being on antibodies. For the past 15 years, vaccine technologies have advanced
considerably. [16]   Examples of malaria vaccine technologies employed in clinical trials are
shown in Table 2.
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CONCLUSION
In the next decade, malaria researchers will develop new, postgenomic resources to move
the field forward both in its basic understanding of plasmodium species biology and its
applied work aimed at control and prevention of the disease. A list of what must be done is
obviously to (i) understand the elements of Plasmodium parasites that enable them to
cause disease and to survive in their hosts and vectors, and to understand which features
of host-parasite, vector-parasite and vector-host relationships present new opportunities
to develop drugs, vaccines and diagnostics; (ii) understand the molecular basis of variation
in phenotypes among malaria parasite strains and species; (iii) understand the key gene
products that are involved in the life of malaria parasites of humans, in stages occurring in
both the host and the mosquito vectors; and (iv) ensure that members of the malaria
community worldwide can use the new tools and knowledge that become available.
Comparative and genome-wide analytical approaches have been made increasingly efficient
through work in Plasmodium  species, animal model systems and human population studies.
All these will help to answer the scientific questions on  malaria.
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